Skip to Main Content

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Conditions

Children's Health

Phase III

What is the purpose of this trial?

Brief Summary:

A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when administered as a rescue therapy for severe hypoglycemia in children with T1DM treated with insulin

  • Trial with
    Zealand Pharma A/S
  • Start Date
    01/28/2019
  • End Date
    06/30/2019
Trial Image

For more information about this study, contact:

Kristen Kraemer

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    03/25/2019
  • Study HIC
    #2000024075